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Abstract
Background: Genetic databases are becoming increasingly common as a means of determining
the relationship between lifestyle, environmental exposures and genetic diseases. These databases
rely on large numbers of research subjects contributing their genetic material to successfully
explore the genetic basis of disease. However, as all possible research questions that can be posed
of the data are unknown, an unresolved ethical issue is the status of informed consent for future
research uses of genetic material.
Discussion: In this paper, we discuss the difficulties of an informed consent model for future
ineffable uses of genetic data. We argue that variations on consent, such as presumed consent,
blanket consent or constructed consent fail to meet the standards required by current informed
consent doctrine and are distortions of the original concept. In this paper, we propose the concept
of an authorization model whereby participants in genetic data banks are able to exercise a certain
amount of control over future uses of genetic data. We argue this preserves the autonomy of
individuals at the same time as allowing them to give permission and discretion to researchers for
certain types of research.
Summary: The authorization model represents a step forward in the debate about informed
consent in genetic databases. The move towards an authorization model would require changes in
the regulatory and legislative environments. Additionally, empirical support of the utility and
acceptability of authorization is required.
Background
Recent developments in genetics, particularly the se-
quencing of the human genome, have energized large-
scale genetics and genomics research. One of the out-
comes has been the establishment of large-scale genetic
data banks aiming to identify genetic predispositions to
major public health conditions that appear to have com-
plex associations rather than being caused by single genet-
ic mutations. Although many small collections have
existed for a long time, none have been on a massive na-
tional scale until recently, when a private Icelandic com-
pany working closely with the government of Iceland
established the Icelandic genetics database  [1]. Specific
legislation had to be passed to enable the creation of that
database. Since then various countries, including Estonia,
have attempted to establish their own national data
banks. The United Kingdom is now in the process of cre-
ating the world's largest such bank. It will be known as
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Biobank and will collect DNA samples from approximate-
ly half a million adults [2].
An important feature of these data banks, and one that is
crucial to their scientific utility, is the ability to link DNA
information with individual clinical outcome data and,
perhaps, relevant non-medical information. As such,
these data banks create profound legal and ethical issues,
especially in areas of privacy, confidentiality and access
[3–5]. In the conventional research setting, these issues
are usually dealt with by obtaining informed consent for
the use of individual health information for research pur-
poses. But while it is possible to obtain informed consent
to have one's blood, cells or tissue sample taken by the re-
searchers for a specific research project, the very intention
of setting up such large data banks precludes giving in-
formed consent for all the possible ways in which the in-
formation derived from that sample can be used for future
research [6]. Given the speed of scientific development in
the area of genetics and the vast spectrum of potential re-
search hypotheses that may arise and can legitimately be
addressed by such databanks, there is no way to predict
possible future uses of donated samples.
In this brief article, we do not propose to resolve the pol-
icy dilemma. Rather, we mean to highlight that much of
the existing literature and policy statements underplay the
stark nature of the relevant policy choices. In the context
of research involving large-scale DNA databanks, it will be
nearly impossible to craft a policy solution that can mean-
ingfully satisfy existing consent norms. The choice for the
public and policy makers is between the research and an
abandonment of existing consent principles. We will dis-
cuss an authorization model that may help to clarify some
of the tensions inherent in consent models.
Discussion
Informed consent
The modern understanding of informed consent in the
context of research is greatly informed by the Nuremburg
code and the large body of ethics literature and analysis
that has emerged since World War II [7]. At the current
time, the legal obligation of informed consent in the re-
search setting is tremendously onerous and has been char-
acterized as "the most exacting duty possible" [8]. At a
minimum, it requires researchers to provide information
about all potential risks, no matter how remote, and ma-
terial information about the nature of the research proto-
col. In the context of clinical genetic research, this consent
process should include, for instance, information about
possible commercialization, how issues of confidentiality
will be addressed, potential impact of participation on in-
surability, and whether the research results will be availa-
ble to the research participant. In the context of clinical
research, few would dispute the value and necessity of this
robust consent process. However, should the same rules
apply to research involving DNA data banks?
Though there are some jurisdictions that have legal frame-
works capable of allowing access to identifiable health in-
formation without consent (e.g., the UK's Health and
Social Care Act 2001), as a general rule the law compels re-
searchers to obtain informed consent for the use of iden-
tifiable health information, including tissue samples. This
is because the law views health information as something
that, as suggested by the Supreme Court of Canada, "goes
to the personal integrity and autonomy of the patient" [9].
And, as such, the patient maintains a "basic and continu-
ing interest in what happens to this information, and in
controlling access to it." [9].
But if we are to allow population genetic research to move
forward, we need to recognize that adherence to this tra-
ditional model of informed consent is problematic. As the
UK Human Genetics Commission recently concluded:
"the difficulties involved in tracing and securing re-con-
sent for different forms of medical research may make ob-
taining fresh consent impractical and would seriously
limit the usefulness of large-scale population databases"
[10].
Population research does have characteristics that seem to
justify a re-assessment of the consent standards. First, as
noted, the purpose and direction of the research may not
be fully known at the time the samples and consent are
obtained. Second, because much of the research involves
low penetrance genes, it is unlikely the research results
will be of immediate clinical relevance to individual re-
search participants [11]. Third, the research and informa-
tion involves large numbers of people, thereby
minimizing the impact and relevance of a single sample.
Fourth, the DNA samples can be collected relatively easily
and involves little physical risk. And finally, the research
may require multiple requests for consent, thus burdening
both researcher and participant, which was noted on a re-
cent public consultation to be a potential disincentive to
participation [12].
Nevertheless, in total, it is difficult to argue that this is re-
search that does not require, at least technically, specific
consent [13]. Consent law is concerned with providing re-
search participants with relevant information in order to
allow autonomous decision-making. Withholding or tai-
loring the provision of information in order to meet a
broader social agenda, conflicts directly with the ethical
principles that underlie much consent jurisprudence.
Moreover, there are aspects of population genetic research
that seem especially important to communicate as part of
an ongoing consent process. For example, the collection
and storage of the DNA samples, particularly when it in-BMC Medical Ethics 2003, 4 http://www.biomedcentral.com/1472-6939/4/1
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volves discrete or identifiable populations, has the poten-
tial to create a variety of social and ethical concerns,
including possible genetic discrimination [14]. In addi-
tion, it might have health and legal implications to third
parties, particularly genetic relatives across several genera-
tions. And, rightly or not, research participants may also
have a continuing interest in the commercial applications
associated with the DNA databank [15].
Policy options
The issue of consent in the context of DNA data banks has
been the subject of a variety of recent policy documents
[10]. Though there seems to be an emerging consensus re-
garding the nature of the consent challenges created by
DNA data banks, most policy recommendations continue
to rely on an unworkable straining of existing consent
principles [16]. The most common recommendation
seems to be the adoption of some form of "blanket con-
sent", that is, a consent form that allows research partici-
pants to make a one-time choice about the future use of
their DNA sample. For example, UNESCO's Draft Report
on Collection, Treatment, Storage and Use of Genetic Data
recommends: "A system which required fresh consent
would be extremely cumbersome and could seriously in-
hibit research .... blanket consent covering all forms of fu-
ture medical research might be preferable [17]. Similarly,
commentators have also suggested using a system of "pre-
sumed consent." Based on the results of a study which
found only 29% of the survey participants would want to
re-consent, Wendler and Emanuel suggest "using pre-
sumed consent with opt-out" [18].
Though a one-time consent would undoubtedly simplify
the research process, blanket consents cannot be consid-
ered true consent. Because blanket consents are necessari-
ly vague, they are, by definition, far too general to have
much legal weight. Moreover, they do not allow patients
to meaningfully act on their continuing interest in their
health information [19]. As such, most types of blanket
consent will, as suggested by Hank Greely, fall "far short
of true informed consent" [20]. A variety of studies of
public opinion have demonstrated a strong desire for a re-
tention of the consent process in this context [21–23]. For
example, a study done by the UK Human Genetics Com-
mission found that 82% of the respondents either strong-
ly agree (44%) or tend to agree (38%) that fresh consent
must be sought from individuals before new research can
be conducted on existing DNA samples held in medical
genetic databases [24].
An alternative is to move away from the "fiction of con-
sent" [13]and recognize that a new legal/ethical frame-
work is required. For example, a more appropriate model
may be that of authorization. Greely has set out a series of
issues that must be addressed in order valid future re-
search on collected genetic samples. His model includes
permission for unforeseen research, recontact of subjects,
the right to withdrawal, setting time limits on the use of
samples, availability of information or materials to third
parties, information on implications for groups and infor-
mation on commercial uses [20].
Whereas individual informed consent would be required
for initial collection of genetic material and health infor-
mation, subsequent uses could be carried out under a
mode of pre-authorization. This could take the form of a
directive, such as a proposed health information directive
that gives participating individuals the ability to pre-spec-
ify uses for which they do or do not wish to give informed
consent in the future [25]. For genetic data banks, partici-
pants may wish only to be contacted if there are clinically
relevant findings, or if potential commercial applications
are being derived. The possibility of a blanket consent ex-
ists, but is not presumed by researchers and can only occur
by the choice of a participant. Each individual can specify
in advance the extent of involvement with decision mak-
ing that is desired. This preserves aspects of autonomy, but
is neither restrictive of future uses as a full consent model,
nor is as permissive as proposed blanket consent models.
Recent research indicates that participants are willing to
consent to research when contacted many years after the
original collection of genetic material, and most would do
so if an ethics review board had approved such studies
[26]. Despite this, it would still be preferable to have such
a process set out in advance rather than always working
retrospectively.
Such an authorization model would need to be structured
with an understanding of the protections and fundamen-
tal rights that are lost through a change of the consent
process – including an understanding of the social and
ethical concerns specific to this area of research (e.g., con-
cern about discrimination and stigmatization). For exam-
ple, the system would need to be bolstered by additional
protection afforded by an overarching governance frame-
work of trust, responsibility and accountability. The in-
volvement of institutional review boards would be
essential. Additionally, a socially constituted, preferably
legally mandated, oversight body operating at arms length
from researchers and commercial interests such as the
Medical Data Panel proposed by the Select Committee on
Science and Technology in the UK, or an ombudsperson,
such as that proposed for electronic health information,
would bolster these additional protections. In many juris-
dictions, such as in Canada, the adoption of an authoriza-
tion model or, for that matter, any scheme that differs
from the existing consent principles, would require the
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Summary
The value of recognizing that existing consent norms are
incapable of accommodating much of the research associ-
ated with DNA data banks is that it forces policy makers
and the public to confront the social tradeoffs inextricably
linked to this work. If we are to adhere to the well-estab-
lished consent norms, a good deal of population research
may not occur. On the other hand, if we abandon the cur-
rent consent model, research participants will be giving up
well established rights and a degree of control. By recog-
nizing the choice, society can more clearly debate the ben-
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